Nanobiotix (NBTX) News Today $3.46 +0.09 (+2.67%) Closing price 01/29/2025 03:59 PM EasternExtended Trading$3.50 +0.04 (+1.01%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025January 29 at 4:15 PM | globenewswire.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest Down 68.6% in JanuaryNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 22,300 shares, a decline of 68.6% from the December 31st total of 71,100 shares. Based on an average daily volume of 29,900 shares, the days-to-cover ratio is currently 0.7 days.January 28 at 8:32 PM | marketbeat.comNanobiotix doses first patient in CONVERGE studyJanuary 21, 2025 | markets.businessinsider.comNANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerJanuary 21, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Trading Down 6.8% - Here's What HappenedNanobiotix (NASDAQ:NBTX) Shares Down 6.8% - Time to Sell?December 20, 2024 | marketbeat.comNanobiotix to Unveil Future of NanotherapeuticsDecember 18, 2024 | markets.businessinsider.comNANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024December 17, 2024 | globenewswire.comNanobiotix S.A.: NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic CancerDecember 10, 2024 | finanznachrichten.deNANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic CancerDecember 9, 2024 | globenewswire.comNanobiotix (NASDAQ:NBTX) Trading Down 3.5% - Should You Sell?Nanobiotix (NASDAQ:NBTX) Shares Down 3.5% - Should You Sell?November 28, 2024 | marketbeat.comNanobiotix’s Market Influence and Innovation UnveiledNovember 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Nanobiotix: Promising Pipeline Progress and Strategic PartnershipsNovember 14, 2024 | markets.businessinsider.comNanobiotix Strengthens Growth and Financial ProspectsNovember 13, 2024 | markets.businessinsider.comNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics PlatformsNovember 12, 2024 | finanznachrichten.deNANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics PlatformsNovember 12, 2024 | globenewswire.comNanobiotix (NASDAQ:NBTX) Trading Up 3.6% - Still a Buy?Nanobiotix (NASDAQ:NBTX) Stock Price Up 3.6% - What's Next?November 6, 2024 | marketbeat.comNANOBIOTIX to Participate in Multiple Investor Conferences in NovemberOctober 31, 2024 | globenewswire.comNanobiotix S.A. ADROctober 18, 2024 | wsj.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest UpdateNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 33,300 shares, a drop of 18.0% from the September 15th total of 40,600 shares. Based on an average daily trading volume, of 9,500 shares, the short-interest ratio is currently 3.5 days.October 13, 2024 | marketbeat.comNanobiotix S.A. (NASDAQ:NBTX) Sees Large Drop in Short InterestNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 40,600 shares, a drop of 19.4% from the August 31st total of 50,400 shares. Based on an average daily volume of 9,600 shares, the short-interest ratio is presently 4.2 days.September 27, 2024 | marketbeat.comBuy Rating on Nanobiotix: Anticipating Key Data Readouts and Solid FinancialsSeptember 21, 2024 | markets.businessinsider.comNanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial ResultsSeptember 19, 2024 | finanznachrichten.deNANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial ResultsSeptember 18, 2024 | globenewswire.comNANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term GrowthSeptember 4, 2024 | globenewswire.comNanobiotix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comNanobiotix (NASDAQ:NBTX) Shares Up 8.5%Nanobiotix (NASDAQ:NBTX) Trading 8.5% HigherJuly 31, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Up 1.2%Nanobiotix (NASDAQ:NBTX) Trading Up 1.2%July 6, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Stock Price Down 14%Nanobiotix (NASDAQ:NBTX) Trading Down 14%June 15, 2024 | marketbeat.comNANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024June 12, 2024 | globenewswire.comNanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 TherapyJune 2, 2024 | globenewswire.comNANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference CallMay 28, 2024 | globenewswire.comLeerink Partnrs Comments on Nanobiotix S.A.'s FY2025 Earnings (NASDAQ:NBTX)Nanobiotix S.A. (NASDAQ:NBTX - Free Report) - Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Nanobiotix in a research report issued to clients and investors on Wednesday, May 22nd. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per shMay 24, 2024 | marketbeat.comNANOBIOTIX to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | globenewswire.comNanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 22, 2024 | finanznachrichten.deNANOBIOTIX Provides First Quarter 2024 Operational and Financial UpdateMay 22, 2024 | globenewswire.comNanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 21, 2024 | globenewswire.comNANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024May 15, 2024 | globenewswire.comNANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung CancerMay 14, 2024 | globenewswire.comNanobiotix's (NBTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating on shares of Nanobiotix in a research report on Friday.April 30, 2024 | marketbeat.comNanobiotix S.A. (NBTX) Q4 2023 Earnings Call TranscriptApril 29, 2024 | seekingalpha.comNanobiotix Stock (NASDAQ:NBTX), Earnings Estimates, EPS, and RevenueApril 26, 2024 | benzinga.comNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsApril 24, 2024 | globenewswire.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024April 17, 2024 | globenewswire.comBaillie Gifford & Co. Has $20.89 Million Stock Holdings in Nanobiotix S.A. (NASDAQ:NBTX)Baillie Gifford & Co. increased its position in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,869,030 shares of the company's stock after buying an aApril 11, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Down 1.6%Nanobiotix (NASDAQ:NBTX) Trading Down 1.6%April 3, 2024 | marketbeat.comNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-IrradiationApril 2, 2024 | globenewswire.comNanobiotix to Present at Upcoming Investor Conferences in MarchMarch 6, 2024 | globenewswire.comNanobiotix S.A. (NASDAQ:NBTX) Shares Bought by Baillie Gifford & Co.Baillie Gifford & Co. raised its holdings in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) by 38.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,936,195 shares of the company's stock after purchaFebruary 17, 2024 | marketbeat.comJohnson & Johnson Buys Shares of 959,637 Nanobiotix S.A. (NASDAQ:NBTX)Johnson & Johnson bought a new stake in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 959,637 shares of the company's stock, valued at approximately $8,397,000.February 12, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Down 2.3% Nanobiotix (NASDAQ:NBTX) Stock Price Down 2.3%February 3, 2024 | marketbeat.com Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBTX Media Mentions By Week NBTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBTX News Sentiment▼1.190.76▲Average Medical News Sentiment NBTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBTX Articles This Week▼41▲NBTX Articles Average Week Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bicara Therapeutics News Today CARGO Therapeutics News Today Dianthus Therapeutics News Today Kura Oncology News Today Pharming Group News Today Tectonic Therapeutic News Today Immunome News Today Autolus Therapeutics News Today Cullinan Therapeutics News Today Humacyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBTX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
